(Q34580659)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

meta-analysis

0 references

title

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

J Hing

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

J J Perez-Ruixo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

K Stuyckens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A Soto-Matos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

P Zannikos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

27 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

130-143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597713%20AND%20SRC:MED&resulttype=core&format=json

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Mechanistic models for myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Mechanism-based models for topotecan-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

A Bayesian population PK-PD model of ispinesib-induced myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Risk models for predicting chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Some suggestions for measuring predictive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

7 January 2021

Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

7 January 2021

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

7 January 2021

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

7 January 2021

Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100259

7 January 2021